Related references
Note: Only part of the references are listed.Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway
Eiji Sakai et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS
Jiang Liu et al.
ONCOTARGETS AND THERAPY (2016)
Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials
Lizhen Zhu et al.
PLOS ONE (2016)
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer
Luisa Foltran et al.
FUTURE ONCOLOGY (2015)
Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer
Shigenori Kadowaki et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
Giuseppe Bronte et al.
ONCOTARGET (2015)
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
Christina Therkildsen et al.
ACTA ONCOLOGICA (2014)
BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients
Jing Chen et al.
BMC CANCER (2014)
The MAPK Pathway Across Different Malignancies: A New Perspective
Mauricio Burotto et al.
CANCER (2014)
Unstable genomes elevate transcriptome dynamics
Joshua B. Stevens et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
George Pentheroudakis et al.
BMC CANCER (2013)
The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
V. Eklof et al.
BRITISH JOURNAL OF CANCER (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis
Zi-Xu Yuan et al.
PLOS ONE (2013)
Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
Yu Imamura et al.
CLINICAL CANCER RESEARCH (2012)
Is K-ras Gene Mutation a Prognostic Factor for Colorectal Cancer: A Systematic Review and Meta-analysis
JiaoJiao Ren et al.
DISEASES OF THE COLON & RECTUM (2012)
Mutations and epimutations in the origin of cancer
Paivi Peltomaki
EXPERIMENTAL CELL RESEARCH (2012)
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
Grazia Palomba et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
T. Yokota et al.
BRITISH JOURNAL OF CANCER (2011)
Global Patterns of Cancer Incidence and Mortality Rates and Trends
Ahmedin Jemal et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Stephan E. Baldus et al.
CLINICAL CANCER RESEARCH (2010)
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
Jolien Tol et al.
EUROPEAN JOURNAL OF CANCER (2010)
Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies
Li-Xin Qiu et al.
EUROPEAN JOURNAL OF CANCER (2010)
Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
Inti Zlobec et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Alberto Bardelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy
Milena Casula et al.
BMC CANCER (2009)
A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population
Grazia Palomba et al.
BMC CANCER (2009)
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
J. Souglakos et al.
BRITISH JOURNAL OF CANCER (2009)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
Shuji Ogino et al.
GUT (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
Shuji Ogino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
BRAF Mutation in Metastatic Colorectal Cancer.
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer
Thomas Winder et al.
ONCOLOGY REPORTS (2009)
Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases
Ludovic Barault et al.
CANCER RESEARCH (2008)
Molecular origins of cancer: Epigenetics in cancer
Manel Esteller
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer
Daniel J. Weisenberger et al.
NATURE GENETICS (2006)
Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening
G Palomba et al.
CANCER (2005)
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
WS Samowitz et al.
CANCER RESEARCH (2005)
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas:: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study
V. Bazan et al.
ANNALS OF ONCOLOGY (2005)
BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility:: The Italian melanoma intergroup study
M Casula et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Epidermal growth factor receptor: mechanisms of activation and signalling
RN Jorissen et al.
EXPERIMENTAL CELL RESEARCH (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
